Type a search term to find related articles by LIMS subject matter experts gathered from the most trusted and dynamic collaboration tools in the laboratory informatics industry.
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C26H25NO |
| Molar mass | 367.492 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
JWH-145 (1-naphthalenyl(1-pentyl-5-phenyl-1H-pyrrol-3-yl)-methanone) is a synthetic cannabinoid from the naphthoylpyrrole family which acts as an agonist of the CB1 (Ki = 14 ± 2nM) and CB2 (Ki = 6.4 ± 0.4nM) receptors, with a moderate (~2.2x) selectivity for the CB2 receptor. JWH-145 was first synthesized in 2006 by John W. Huffman and colleagues to examine the nature of ligand binding to the CB1 receptor.[1]
In the United States JWH-145 is not federally scheduled, although some states have passed legislation banning the sale, possession, and manufacture of JWH-145.[2][3][4][5]
In Canada, JWH-145 and other naphthoylpyrrole-based cannabinoids are Schedule II controlled substances under the Controlled Drugs and Substances Act.[citation needed]
In the United Kingdom, JWH-145 and other naphthoylpyrrole-based cannabinoids are considered Class B drugs under the Misuse of Drugs Act 1971.[citation needed]
LIMS forum content by LIMS forum members is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at www.limsforum.com.
